Cantor Fitzgerald analyst Pete Stavropoulos initiated coverage of CervoMed (CRVO) with an Overweight rating and no price target CervoMed has generated “intriguing” data in two Phase 2 studies for neflamapimod in dementia with Lewy bodies and the upside opportunity for shares is significant, the analyst tells investors in a research note. Neflamapimod aims to reduce degeneration of cholinergic neurons by impacting several biological pathways, which may lead to disease-modifying activity and slowing the rate of decline, the firm says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed Initiated With Buy Rating on Differentiated DLB Asset Neflamapimod and De-Risked Path to 2029 Launch
- CervoMed’s Promising Phase 2b Trial Results for DLB
- CervoMed’s neflamapimod shows efficacy in slowing dementia
- Optimistic Buy Rating for CervoMed Following Promising Phase 2b Trial Results and Strategic Insights
- CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod